Sanofi has scored FDA approval for its subcutaneous version of Sarclisa, giving the multiple myeloma treatment a potential ...
Regulatory clearance adds a 1,400-mg subcutaneous CD38 antibody option using CirCLIQ on-body delivery or provider-administered injection, maintaining the same active medicine as the IV formulation.
FDA clears subcutaneous Sarclisa Escena for multiple myeloma, showing comparable overall response rates to IV delivery.
Approval covers all current IV isatuximab indications and introduces the first oncology product labeled for both OBI and manual SC administration. IRAKLIA (NCT05405166) established noninferiority of ...
4don MSN
Understanding Ozempic, Wegovy, and Mounjaro: What you need to know about these weight-loss therapies
These are not lifestyle shortcuts. They are prescription medicines, and the benefits come with possible side effects ...
Inhalers are often used for asthma, a condition in which the lungs struggle to get enough air absorbed and sent to the body.
July 10 (Reuters) - The U.S. Food and Drug Administration said on Friday it has approved Sanofi's blood cancer drug, Sarclisa, which can be given under the skin through a wearable injector, offering ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results